
News|Videos|December 18, 2024
Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
Author(s)Steven M. Horwitz, MD
Steven Horwitz, MD, presents the final results of the Phase 2 PRIMO trial, highlighting the efficacy and safety of duvelisib as a promising treatment option for relapsed/refractory peripheral T-cell lymphoma, with insights into overall response rates, progression-free survival, and adverse event management.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
4
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
5




































